The survival penalty: Age-based inequities in hypertension and diabetes management in African health systems (1990–2022) – a secondary quantitative analysis Authors: Lawrence Ejike Ugwu, Bruno Basil, Uzoamaka Francisca Ugwoke, Effiness Harawa Kamanga, Ngozi Ijeoma Okoro, Emmanuel Olamijuwon, Priyanka Roy, Priyanka Roy Published: 2026 ABSTRACT Africa is experiencing rapid population ageing, yet many health systems remain oriented towards acute and infectious disease care. Whether population-level indicators of hypertension and diabetes management remain comparable across older age groups is unclear. We assessed age-associated differences in chronic disease care cascade indicators across African Union member states using age-stratified estimates from the NCD Risk Factor Collaboration (NCD-RisC). We analysed country-year estimates for hypertension (1990–2019) and diabetes (1990–2022), comparing a working-age reference group (50–54 years), a young-old group (65–69 years), and the oldest available age groups (75–79 years for hypertension and ≥85 years for diabetes). Outcomes included diabetes treatment coverage, hypertension diagnosis, treatment and control, and the prevalence of severe untreated hypertension (stage 2; BP > 160/100 mmHg). The analysis included NCD-RisC estimates derived from 2,309 population-based studies involving 245 million participants. Hypertension prevalence was higher in adults aged 75–79 years than those aged 50–54 years (64·4% vs 42·6%; relative risk 1·51). Although diagnosis was more frequent among older adults (53·3% vs 42·6%), hypertension control remained lower (11·6% vs 16·9%). Diabetes treatment coverage declined after age 70, falling from 32·9% in adults aged 65–69 years to 23·1% in those aged ≥85 years (difference 9·8 percentage points; 95% UI 5·9–13·7). Severe untreated hypertension was more common in adults aged 75–79 years than in those aged 50–54 years (29·8% vs 26·6%), with the highest prevalence in Central and West Africa. Across Africa, diabetes treatment coverage and hypertension control declined with advancing age despite higher diagnosis rates, while severe untreated hypertension remained common among older adults. These findings support incorporating age-specific chronic disease cascade indicators into Universal Health Coverage monitoring and strengthening health systems to improve cardiovascular risk management in ageing populations. Research in context Evidence before this study We searched PubMed and Google Scholar for studies published between Jan 1, 1990, and Dec 31, 2024, using terms including “Africa”, “hypertension”, “diabetes”, “older adults”, “elderly”, “health system performance”, “cascade of care”, and “age inequities”. While there is robust evidence documenting the rising burden of non-communicable diseases (NCDs) in Africa and the demographic shift towards an ageing population, most health system analyses treat “adults” as a homogeneous group or focus primarily on prevalence. Few studies have explicitly compared care cascade indicators in the “oldest-old” (e.g., ≥≥ 75 or ≥80 years) with younger adult cohorts across multiple African countries, and evidence on factors contributing to observed age gradients remains limited and fragmented. Added value of this study This is, to our knowledge, the first continental analysis to describe age-stratified inequities in NCD management across all 54 African Union member states using harmonised NCD-RisC estimates for hypertension (1990–2019) and diabetes (1990–2022). We quantify age-associated differences in diabetes treatment coverage after age 70 and examine hypertension cascade indicators alongside the burden of severe untreated hypertension (BP >> 160/100 mmHg) as a public-health risk marker. We also describe geographic and sex-stratified heterogeneity in these patterns and identify countries with comparatively smaller age gradients as potential case studies for further investigation. Implications of all the available evidence The evidence indicates that Universal Health Coverage (UHC) expansion may be associated with uneven patterns across age groups if age-specific retention and treatment intensity are not monitored. Because treatment targets and clinical decision-making may differ in very old or frail adults, age gradients should be interpreted cautiously; however, high levels of severe untreated hypertension remain a clear signal of avoidable risk. Policy and programmatic responses should include age-responsive monitoring of cascade indicators, strengthened continuity of chronic care, and safeguards to ensure older adults are not disproportionately disadvantaged in access to care. Introduction Africa is entering rapid population ageing, yet its health systems were built for acute, maternal, and infectious disease care [1,2]. Whether these systems can deliver long-term, equitable chronic care to older adults is unclear. As life expectancy increases across the continent, the burden of non-communicable diseases (NCDs) is shifting toward later life [2,3]. However, current Universal Health Coverage (UHC) frameworks often prioritise coverage expansion and enrolment metrics [4], and it remains uncertain whether gains in detection translate into sustained treatment and control for the oldest age groups [5]. We use the term “survival penalty” as a descriptive construct for age-associated shortfalls in cascade performance at advanced ages, without implying a specific underlying mechanism. Emerging signals raise the possibility that chronic care cascades may show steeper age-related declines in some African settings [6–8]. We hypothesised that diabetes treatment coverage may decline after age 70 (“post-70 drop-off”), and that hypertension management may show a substantial diagnosis–control gap in older adults [9,10]. Because the present study uses aggregated, modelled estimates, we interpret observed patterns as descriptive age gradients and do not infer causality or underlying system intent. Herein, we evaluate national health system performance across 54 African Union member states to quantify age-based differences in NCD management. Using aggregated, age-stratified estimates from the NCD Risk Factor Collaboration (NCD-RisC) covering hypertension (1990–2019) and diabetes (1990–2022), we describe how cascade indicators vary by age, sex, and subregion, and we identify the points in the cascade where older-age differences are most pronounced. Methods Ethics statement This research involves a secondary quantitative analysis of publicly available, aggregated, and anonymized population health estimates. As the study utilized data that contained no individual-level identifiers and was accessed via the NCD Risk Factor Collaboration (NCD-RisC) public repository, it was exempt from institutional review board (IRB) approval. Participant recruitment, ethical oversight, and the acquisition of formal consent were conducted by the primary investigators of the original population-based surveys synthesized by NCD-RisC. Formal consent for this specific secondary analysis was not obtained because the data were fully anonymized and aggregated at the national, age, and sex levels prior to our access and analysis. Study design This study is a secondary, ecological analysis of aggregated, age-stratified population health estimates for the 54 African Union member states. We utilised posterior mean estimates from the NCD Risk Factor Collaboration (NCD-RisC), accessed between 12th and 25th October 2025, to describe age patterns in hypertension and diabetes care cascade indicators. Because inputs are modelled and aggregated, analyses describe population-level gradients and do not support causal attribution about individual clinical decisions or intent. The study follows the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) and relevant STROBE reporting items for observational analyses. Data sources and handling Two specific datasets were analysed: Hypertension (1990–2019): Estimates of prevalence, diagnosis, treatment, and control rates were derived from 1,201 population-based studies involving 104 million participants. Hypertension (1990–2019): Estimates of prevalence, diagnosis, treatment, and control rates were derived from 1,201 population-based studies involving 104 million participants. Diabetes (1990–2022): Estimates of prevalence and treatment coverage were derived from 1,108 comparable national surveys involving 141 million participants. Diabetes (1990–2022): Estimates of prevalence and treatment coverage were derived from 1,108 comparable national surveys involving 141 million participants. The NCD-RisC estimates are generated using a Bayesian hierarchical model that incorporates nonlinear time trends and age patterns to account for data scarcity in select nations; the underlying model inputs incorporate study-level adjustments and, where applicable, survey sampling weights as described in NCD-RisC methodological documentation. We used the country-year-age group estimates without further imputation. Procedures and definitions To evaluate age-associated gradients in care cascade indicators, we stratified the population into three functional age categories based on available NCD-RisC age strata: The Workforce (Reference Group): Adults aged 50–54 years, selected as a stable late-career working-age reference group for cross-country comparison. The Workforce (Reference Group): Adults aged 50–54 years, selected as a stable late-career working-age reference group for cross-country comparison. The “Young-Old”: Adults aged 65–69 years, representing the transition to retirement. The “Young-Old”: Adults aged 65–69 years, representing the transition to retirement. The “Oldest-Old”: Adults aged 75–79 years for hypertension (the oldest 5-year band available in the hypertension cascade estimates) and ≥85 years for diabetes (the oldest open-ended stratum available in the diabetes treatment estimates). The “Oldest-Old”: Adults aged 75–79 years for hypertension (the oldest 5-year band available in the hypertension cascade estimates) and ≥85 years for diabetes (the oldest open-ended stratum available in the diabetes treatment estimates). Outcomes Primary outcomes were age-related differences in chronic care cascade indicators (descriptive): Diabetes treatment coverage drop-off: Diabetes treatment coverage in 2022, summarised as the percentage-point difference between the “Young-Old” (65–69 years) and the “Oldest-Old” (≥85 years). Larger positive differences indicate larger age-related gaps in treatment coverage. Diabetes treatment coverage drop-off: Diabetes treatment coverage in 2022, summarised as the percentage-point difference between the “Young-Old” (65–69 years) and the “Oldest-Old” (≥85 years). Larger positive differences indicate larger age-related gaps in treatment coverage. Hypertension cascade gaps and severe untreated burden: Using hypertension estimates in 2019, we describe (i) diagnosis, treatment, and control levels; (ii) the diagnosis–control gap as a summary of downstream management shortfalls; and (iii) the prevalence of severe untreated (stage 2) hypertension (systolic BP > 160 mmHg or diastolic BP > 100 mmHg) as a public-health risk marker. These indicators do not isolate specific failure points (e.g., initiation vs adherence vs intensification) and should not be interpreted as direct measures of clinician behaviour. Control thresholds follow standard guideline definitions for hypertension management in adults [11]. Hypertension cascade gaps and severe untreated burden: Using hypertension estimates in 2019, we describe (i) diagnosis, treatment, and control levels; (ii) the diagnosis–control gap as a summary of downstream management shortfalls; and (iii) the prevalence of severe untreated (stage 2) hypertension (systolic BP > 160 mmHg or diastolic BP > 100 mmHg) as a public-health risk marker. These indicators do not isolate specific failure points (e.g., initiation vs adherence vs intensification) and should not be interpreted as direct measures of clinician behaviour. Control thresholds follow standard guideline definitions for hypertension management in adults [11]. Sub-regional and gender analysis Countries were stratified into five subregions (Central, East, North, Southern, and West Africa) according to African Union designations. Sex-stratified analyses were conducted to describe whether age gradients differed between men and women. Statistical analysis The unit of analysis was the national health system (N = 54). We summarised country-level posterior mean estimates and computed percentage-point differences between age groups for each country (e.g., diabetes 65–69 minus ≥85; hypertension 75–79 minus 50–54 for severe untreated stage 2). We report descriptive statistics (means, ranges) and present graphical summaries and country rankings. As an additional sensitivity analysis and robustness check against cut-point sensitivity (to assess whether observed age-related patterns are sensitive to specific age thresholds rather than to infer causal effects), we visualise age-cohort profiles across all available age bands for key indicators (Fig 2A). We avoided conventional hypothesis testing because posterior uncertainty and cross-country dependence are not fully represented by point estimates alone. Descriptive epidemiology: ageing patterns in hypertension and diabetes and the diagnosis–control gap. (A) Hypertension prevalence in 1990 vs 2019, comparing 50–54 vs 75–79. (B) Diabetes prevalence in 1990 vs 2022, comparing 65–69 vs ≥ 85. (C) Diagnosis versus control for hypertension in 2019, comparing 50–54 vs 75–79. Uncertainty propagation for derived differences: NCD-RisC provides posterior means and 95% uncertainty intervals (UIs) for each estimate. To propagate uncertainty into derived gaps (e.g., diabetes treatment coverage at ages 65–69 minus ≥85), we approximated the standard error (SE) from the published 95% UI as SE = (Upper UI − Lower UI) / (2 × 1·96). Assuming independence between age-stratified estimates within a given year (a conservative assumption because age-specific posteriors are likely positively correlated), the SE of an age-group difference was computed as SE diff = √(SE_A² + SE_B²), and the 95% UI for the gap as Gap mean ± 1·96 × SE_diff. Because uncertainty is widest for the oldest age bands at the country level, we additionally summarised interval-based differences at regional and continental levels. For these pooled analyses, we first derived a single country-level estimate for both sexes (using the NCD-RisC both-sex estimate where available; otherwise, averaging sex-specific estimates within country and pooling their SEs), then computed unweighted means across countries and pooled SEs for the mean as √(ΣSE_i²) / N. A gap was interpreted as supported by the modelled uncertainty when its 95% UI excluded zero. Analyses were performed using R (version 4.5.2). Results Study characteristics Data were available for all 54 African Union member states. We analysed hypertension estimates (1990–2019) and diabetes estimates (1990–2022) to evaluate age-based inequities in health system performance. Hypertension burden, detection, and control The burden of hypertension was concentrated in later life (Fig 1A). Mean prevalence was higher among older adults (75–79 years) compared with the working-age reference group (50–54 years) (64·4% vs 42·6%; relative risk 1·51) (Table 1). Diagnosis rates were higher in the 75–79 cohort (53·3%) than in the 50–54 cohort (42·6%). However, blood pressure control remained low in both groups (11·6% vs 16·9%), indicating a substantial difference between diagnosis and control levels (Fig 1C). 10.1371/journal.pgph.0006306.t001Table 1Hypertension cascade indicators comparing adults aged 50–54 years with older adults aged 75–79 years.MetricWorkforce(50–54 Years)Geriatric(75–79 Years)Relative Risk / TrendBurden (Prevalence)42.59%64.4%1.51 × higher prevalence in older adults.Diagnosis/awareness (among those with hypertension)42.61%53.3%Higher diagnosis in older adults (+10.7 percentage points).Outcome (Control)11.60%16.9%Low control in both groups.Risk (Untreated Stage 2)26.61%29.8%Higher severe untreated burden in older adults. Note: Prevalence and untreated stage 2 hypertension are population prevalences (% of all adults in the age band). Diagnosis/awareness, treatment, and control are cascade indicators expressed as proportions among individuals with hypertension in the same age band (as provided by NCD‑RisC). Because these quantities have different denominators, they should not be interpreted as directly comparable percentages. Hypertension cascade indicators comparing adults aged 50–54 years with older adults aged 75–79 years. Note: Prevalence and untreated stage 2 hypertension are population prevalences (% of all adults in the age band). Diagnosis/awareness, treatment, and control are cascade indicators expressed as proportions among individuals with hypertension in the same age band (as provided by NCD‑RisC). Because these quantities have different denominators, they should not be interpreted as directly comparable percentages. Diabetes treatment coverage: Post-70 decline Diabetes prevalence was lower in the oldest-old (≥85 years) compared with the young-old (65–69 years) (Fig 1B). Treatment coverage nevertheless declined after age 70 (Fig 2A), from 32·9% in the 65–69 cohort to 23·1% in the ≥ 85 cohort (difference 9·8 percentage points). When propagating uncertainty from published 95% uncertainty intervals and aggregating across countries, the continental treatment coverage drop-off remained positive (9·8 percentage points; 95% UI 5·9 to 13·7). Inequities in severe clinical risk To quantify severe clinical risk, we examined severe untreated hypertension (stage 2; BP > 160/100 mmHg). Among older adults (75–79 years), the prevalence of severe untreated hypertension was 29·8%, exceeding the control rate in the same age group (16·9%) and the severe untreated prevalence in the working-age comparator (50–54 years: 26·6%) (Fig 2B; Table 1). Because severe untreated hypertension can reflect multiple points of failure (initiation, access, adherence, follow-up, or treatment intensification), we interpret this indicator as a public-health risk marker rather than a direct measure of clinician behaviour or treatment intensification. Geographic heterogeneity in age-related gaps Age-related gaps were not geographically uniform. For diabetes, point-estimate differences in treatment coverage between ages 65–69 and ≥85 varied by subregion (Fig 3; Table 2). Interval-based aggregation indicated that the post-70 drop-off was most robust in East Africa, where the 95% uncertainty interval for the regional drop-off did not include zero (95% UI 6·6 to 19·1). In other regions, treatment coverage also tended to be lower at ≥85, but uncertainty intervals for the aggregated regional differences overlapped zero, consistent with wider uncertainty in the oldest age band and heterogeneous country patterns. 10.1371/journal.pgph.0006306.t002Table 2Posterior mean treatment coverage at ages 65–69 and ≥85 years, and the age-related difference (65–69 minus ≥85), by African Union region.African Union RegionCoverage (65–69)Coverage (85+)Drop-off ScoreInterpretationEast Africa37.3%22.8%14.4% ptsLargest age-related drop in coverage.Southern Africa30.9%19.8%11.1% ptsLarge age-related drop in coverage.North Africa58.6%49.4%9.2% ptsHighest absolute coverage; age gradient persists.Central Africa24.7%18.0%6.7% ptsLow coverage at both ages; smaller drop reflects low baseline.West Africa26.2%19.7%6.5% ptsLow coverage at both ages; modest age-related drop. Posterior mean treatment coverage at ages 65–69 and ≥85 years, and the age-related difference (65–69 minus ≥85), by African Union region. Age patterns in diabetes treatment coverage and severe untreated hypertension. (A) Diabetes treatment coverage by age cohort (2022), showing lower coverage at older ages. (B) Hypertension control and severe untreated stage 2 hypertension (2019) across age cohorts. Regional differences in diabetes treatment coverage by age (2022). Posterior mean treatment coverage at 65–69 years versus ≥85 years, and the resulting age-related difference, by African Union region. For hypertension, most individual countries showed higher severe untreated stage 2 prevalence in older adults (75–79 years) than in the workforce comparator (50–54 years) (Fig 4). Regionally, severe untreated stage 2 prevalence among adults aged 75–79 years was highest in Central Africa (34·5%) and West Africa (32·7%) (Fig 5; Table 3). 10.1371/journal.pgph.0006306.t003Table 3Proportion of the older adult population living with untreated severe hypertension (BP > 160/100 mmHg).RegionPrevalence (Burden)Untreated Stage 2 (Risk)StatusCentral Africa66.7%34.5%Highest severe untreated stage 2 prevalence.West Africa62.4%32.7%High severe untreated stage 2 prevalence.East Africa60.3%28.8%Moderately high severe untreated stage 2 prevalence.Southern Africa67.2%27.7%Lower severe untreated stage 2 prevalence than Central/West.North Africa72.9%20.2%Lowest severe untreated stage 2 prevalence. Proportion of the older adult population living with untreated severe hypertension (BP > 160/100 mmHg). Disparity in untreated severe hypertension (2019): difference in the prevalence of untreated Stage 2 hypertension (BP > 160/100 mmHg) comparing older adults (75–79) with the workforce comparator (50–54) by country. Positive values indicate a higher, severe, untreated burden in older adults. Severe untreated stage 2 hypertension among older adults (2019). Proportion of adults aged 75–79 years living with untreated stage 2 hypertension (BP > 160/100 mmHg) by African Union region. Tunisia was an outlier with comparatively small age differences in diabetes treatment coverage across older age bands (Fig 7C). This descriptive finding suggests that smaller age gradients are achievable within the region, but the underlying system features require further investigation. Cascade gaps and temporal dynamics. (A) Hypertension cascade indicators in older adults (75–79): proportions diagnosed, treated, and controlled. (B) Top 10 countries with the largest diabetes treatment coverage difference between 65–69 and ≥85. (C) Longitudinal trajectory (1990–2019) of the elderly–workforce difference in severe untreated stage 2 hypertension. A–C Modifiers and potential success models. (A) Sex-stratified diabetes treatment coverage at 65–69 vs ≥ 85. (B) Initiation versus downstream management gaps in older adults (75–79): diagnosed but untreated versus treated but uncontrolled, presented as descriptive components of cascade shortfalls. (C) Countries showing comparatively small age differences (or parity) for ≥85 in diabetes treatment coverage. Sex difference in untreated Stage 2 hypertension (75–79): country-level comparison of severe untreated risk in men vs women. Mechanisms and temporal trends Cascade patterns indicated that age-related differences were most pronounced downstream of diagnosis for hypertension: among older adults diagnosed with hypertension, a substantial proportion were treated but not controlled (Fig 6A). For diabetes, country-level point estimates showed marked variation in the 65–69 versus ≥85 treatment coverage difference (Fig 6B); however, country-level inference is limited by wide uncertainty in the ≥ 85 estimates. Longitudinally, the elderly–workforce difference in severe untreated stage 2 hypertension increased from 14.6 percentage points in 1990 to 21.8 in 2019 (Fig 6C). Modifiers Gender-stratified analyses revealed heterogeneous patterns. Sex differences in the diabetes treatment coverage difference suggested that age gradients may not be uniform for men and women (Fig 7A), while country-level data showed substantial variation in severe untreated stage 2 hypertension by sex (Fig 7D). Analyses comparing initiation and downstream management gaps suggest that observed control differences at older ages are more consistent with downstream management shortfalls (treated but uncontrolled) than with low treatment initiation alone, while recognising that these components cannot be causally separated using aggregated data (Fig 7B). Discussion Our ecological analysis of age-stratified, modelled estimates suggests that African health systems exhibit patterns consistent with a systematic “survival penalty” in the management of non-communicable diseases (NCDs), whereby the intensity of care appears to weaken with advancing age despite rising disease burden. Older adults carried a substantially higher prevalence of hypertension yet achieved no meaningful advantage in control, creating a diagnostic paradox in which increased detection failed to translate into protection from severe clinical risk. For diabetes, treatment coverage peaked in the “young-old” and declined sharply in the oldest-old age groups, revealing an age-related reduction in service intensity that is not aligned with expected clinical need. These patterns were not uniform but clustered geographically, with East and Southern Africa showing the greatest shortfalls in diabetes treatment while Central and West Africa carried the highest burden of severe untreated hypertension. Longitudinally, these age-related inequities appear to have widened since 1990, indicating that health system gains may have disproportionately benefited younger cohorts. These findings point to age-based inequities as a potentially structural feature of African NCD systems, rather than a transient anomaly. The diagnosis–control gap observed for hypertension indicates that increased diagnostic contact at older ages does not necessarily translate into sustained control. Several explanations are plausible, including inconsistent medication availability, episodic follow-up, suboptimal titration, and adherence barriers [12,13]. In addition, treatment targets and therapeutic aggressiveness may differ for frail older adults because of polypharmacy, orthostatic hypotension, and competing risks [14–16]; therefore, low control should not be interpreted as inappropriate care in all cases. Nonetheless, persistent severe untreated hypertension suggests that avoidable risk remains substantial in many settings. For diabetes, treatment coverage showed a marked post-70 decline when comparing ages 65–69 with ≥85. This pattern could reflect a combination of factors, including access and affordability barriers, differential clinical targets in very old age, and survivorship bias (healthy survivor effect), whereby older age groups represent a selected subset of individuals who have survived earlier mortality risks, as well as measurement limitations in the underlying surveys [17,18]. This may also contribute to the observed lower prevalence of diabetes in the ≥ 85 cohort. In the absence of explicit geriatric guidelines and robust trial evidence, declining diabetes treatment at advanced ages may also be consistent with clinical decision-making under uncertainty regarding benefit in very old patients, including potential therapeutic inertia [19,20]. The ecological design cannot distinguish among these explanations, but the magnitude and consistency of the decline across multiple settings warrants attention as a potential equity and service-delivery issue. Severe untreated stage 2 hypertension among adults aged 75–79 years remains highly prevalent in Central and West Africa, reflecting gaps in treatment and follow-up. Given that severe hypertension is a modifiable risk factor for stroke and heart failure and that intensive control yields substantial risk reduction, this burden is particularly concerning [21–23]. Importantly, severe untreated burden is compatible with multiple cascade failures (non-initiation, interruption of therapy, inadequate intensification, or limited follow-up), emphasising that detection alone is an incomplete indicator of system performance [24]. The pronounced regional gradients argue against a purely biological explanation and instead point to health system factors as likely contributors to the observed differences, although causal attribution cannot be established. North Africa, with higher treatment coverage and lower severe untreated burden, resembles more developed chronic care models, whereas other regions show patterns consistent with gaps in access and continuity of care, particularly at older ages [25]. Tunisia’s comparatively small age differences in diabetes treatment coverage highlight that smaller age gradients are achievable within Africa, although further comparative work is needed to identify the specific policies or delivery features associated with this pattern [26]. The widening gap in untreated severe hypertension between older adults and the working-age population suggests that age-related inequities have not narrowed over time and may be increasing. This pattern is consistent with health system improvements disproportionately benefiting younger cohorts, leaving the oldest-old relatively underserved, a dynamic aligned with the concept of stratified universalism [27]. However, these trends should be interpreted alongside potential influences of data availability, model performance, and survivorship effects, and warrant confirmation using complementary data sources. A major strength of this study is the use of the largest harmonised dataset of age-stratified NCD care cascades available for Africa, covering all 54 African Union member states over three decades. The use of nationally representative, model-based estimates allows for direct comparison across countries and time. Nonetheless, certain limitations should be taken into account. Our analysis relies on aggregated modelled data rather than individual-level clinical records, which precludes adjustment for comorbidities, frailty, or treatment adherence and service availability. Additionally, the absence of an explicit 80 + hypertension stratum required the use of the 75–79 group as a proxy, which may underestimate age-related differences in hypertension indicators. Differences in upper age strata across conditions may also limit direct comparability of estimates. Finally, diagnostic and treatment definitions reflect available survey data rather than guideline-concordant clinical care, and uncertainty for derived estimates was propagated from published 95% intervals under assumptions of independence, such that correlations within the underlying models may influence the precision of reported differences. For practice, these findings highlight the need to manage older adults with NCDs as a high-risk group requiring proactive titration and continuity rather than passive maintenance. Clinical guidelines should explicitly include age-specific escalation protocols to counter therapeutic inertia. For policy, UHC frameworks must move beyond simple enrolment metrics toward equity-sensitive performance measures that track severe untreated risk in older adults. Financing packages should explicitly protect the oldest-old from potential age-related disparities in access to care. Future research should integrate longitudinal cohort data to identify the specific mechanisms underlying observed age-related differences and evaluate positive-deviant systems, such as Tunisia, to inform the design of age-equitable chronic care models in resource-constrained settings while triangulating findings with complementary data sources where possible. Conclusion In conclusion, current African health systems appear to exhibit patterns consistent with a structural “survival penalty,” where the dividends of increased longevity are not consistently matched by sustained access to effective chronic care for the oldest-old. The divergence between high diagnostic visibility and low levels of disease control in hypertension, coupled with lower treatment coverage among older adults in diabetes care, indicates that Universal Health Coverage frameworks may be associated with age-related differences in care delivery across the life course. These findings challenge the assumption that expanding health access for the general population will automatically benefit geriatric cohorts; instead, they suggest a misalignment in which care intensity does not consistently correlate with clinical need across the life course. Without deliberate policy intervention to integrate geriatric-competent care into primary health platforms, the rising tide of NCDs risks disproportionately affecting the continent’s most vulnerable elders. Achieving true equity requires a more explicit and intentional redesign of service delivery, to ensure that the right to health does not diminish with advancing age. 15 Mar 2026 PGPH-D-26-00316 The survival penalty: age-based inequities in hypertension and diabetes management in African health systems (1990–2022) – a secondary quantitative analysis. PLOS Global Public Health Dear Dr. Basil, Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Apr 29 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Emmanuel Olamijuwon, Ph.D Academic Editor PLOS Global Public Health Journal Requirements: 1. Please ensure that your Ethics Statement is available in its entirety at the beginning of your Methods section, under a subheading 'Ethics Statement'. It must include: i) The name(s) of the Institutional Review Board(s) or Ethics Committee(s) ii) The approval number(s), or a statement that approval was granted by the named board(s) iii) (for human participants or donors) - A statement that formal consent was obtained (must state whether verbal/written) OR the reason consent was not obtained (e.g., anonymity). 2. Please provide separate figure files in .tif or .eps format. For more information about figure files please see our guidelines: https://journals.plos.org/globalpublichealth/s/figures https://journals.plos.org/globalpublichealth/s/figures#loc-file-requirements 3. In the online submission form, you indicated that “The data that support the findings of this study are available from the NCD Risk Factor Collaboration (NCD-RisC) at www.ncdrisc.org. The specific age-stratified aggregate estimates for hypertension and diabetes used in this analysis are publicly available for download. No individual participant data were used. The R code used for the calculation of the Geriatric Drop-off Score and the analysis of therapeutic inertia is available from the corresponding author upon reasonable request.”. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons by return email and your exemption request will be escalated to the editor for approval. Your exemption request will be handled independently and will not hold up the peer review process, but will need to be resolved should your manuscript be accepted for publication. One of the Editorial team will then be in touch if there are any issues. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented. Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Partly Reviewer #5: Yes Reviewer #6: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Yes Reviewer #6: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Yes Reviewer #6: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Yes Reviewer #6: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: General assessment This manuscript addresses an important and understudied question: whether chronic disease management for hypertension and diabetes differs systematically by age across African health systems. The continental scope and use of age-stratified care cascade estimates are potentially valuable, and the descriptive signal reported (declining treatment coverage/control at older ages) is policy-relevant. However, in its current form, the manuscript overinterprets modeled aggregate estimates and employs causal/intentional language that is not supported by the design. Substantial revisions are required before the conclusions are justified. Major issues (must address) 1. Claims exceed what the data/design can support (mechanism/intent language). The manuscript repeatedly uses terms implying intent or discrimination (e.g., “active exclusion,” “withdrawal,” “implicit rationing,” “health system ageism,” “survival penalty”). With ecological, modeled, aggregate NCD-RisC estimates, the study can robustly describe age-associated gradients in cascade indicators, but it cannot attribute intent, decision-making, or mechanisms (e.g., “exclusion” vs “appropriate deprescribing” vs selective survival vs measurement limitations). Required revision: Reframe primary findings as descriptive age gradients/inequities. If terms like “exclusion” or “ageism” are retained, they must be explicitly defined as descriptive constructs, and the limits of inference must be stated clearly in Methods/Limitations. 2. Uncertainty is not propagated; inferential testing is not well justified. The analysis uses posterior mean estimates from NCD-RisC and applies paired t-tests and p-values as if they were directly observed measurements. This ignores estimation uncertainty (credible intervals/posterior distributions) and complicates the interpretation of p-values when using model-based inputs and accounting for cross-country dependence. Required revision: Incorporate uncertainty-aware comparisons (e.g., using posterior intervals or draws where available), and report effect sizes with uncertainty rather than relying on p-values. If inferential statistics are retained, the manuscript must justify the inferential target (e.g., country-level comparative statistics) and clarify the assumptions. 3. Age-band definitions and comparators are inconsistent and appear ad hoc. Hypertension “oldest-old” is 75–79, whereas diabetes “oldest-old” is ≥85; the “workforce” comparator is 50–54 for hypertension, but diabetes comparisons center on 65–69 vs ≥85. This will be read as selective framing unless justified by data availability and sensitivity analyses. Required revision: Provide a principled rationale tied to available age strata, and add sensitivity analyses using alternative age cut points or using age as an ordered series to test the “care cliff” hypothesis (e.g., segmented trend after age 70). 4. Operational definitions need tightening (inertia vs untreated Stage 2). The manuscript defines “therapeutic inertia” as a diagnosis–control gap, but then uses “untreated Stage 2 hypertension” as the main indicator. Severe untreated hypertension reflects multiple failure points (non-initiation, access barriers, adherence, follow-up gaps) and is not synonymous with inertia among treated patients. Required revision: Separate cascade failure mechanisms explicitly: • diagnosed but not treated (initiation gap), • treated but uncontrolled (intensification/management gap), • severe untreated hypertension burden (public health risk indicator). Use terminology consistent with what is actually measured. 5. Internal consistency of numbers/tables must be audited. Several values appear inconsistent across text and tables (e.g., control rates by age group; prevalence and diagnosis appearing identical in Table 1 for the workforce). Reviewers will flag these as credibility issues. Required revision: Reconcile all reported values across Abstract/Results/Tables/Figures; explicitly label the direction of comparisons (“Workforce: x% vs Oldest-old: y%”). 6. Data/code availability does not meet typical PLOS expectations. While the NCD-RisC estimates are public, the manuscript states that the analysis code is available “upon reasonable request.” Required revision: Provide public access to the R code and derived metrics definitions (e.g., OSF/Zenodo/GitHub with a DOI if possible), sufficient for reproduction. Minor issues/clarifications • Guideline/target interpretation in very old age: The Discussion should explicitly acknowledge that treatment targets and therapeutic aggressiveness may differ in frail older adults and that some proportion of lower coverage could reflect clinical appropriateness; then justify why the observed magnitude/pattern still warrants concern, especially for severe untreated hypertension. • Terminology density: The manuscript introduces multiple coined phrases (“care cliff,” “severity trap,” “male malus,” “female decline,” “diagnostic paradox”). Consider reducing or consolidating to improve clarity and reduce rhetorical tone. • Reporting standards: If claiming STROBE/GATHER adherence, ensure the Methods include clear mapping to these items (variables, uncertainty, analytical choices). • References formatting: The reference list shows numbering/formatting errors and should be corrected. Summary recommendation The study question is compelling and could make a useful descriptive contribution. However, the manuscript requires major revision to align claims with the limitations of modeled aggregate data, incorporate uncertainty appropriately, justify age-band choices, clarify outcome definitions, and address internal inconsistencies and issues with reproducibility. Reviewer #2: Given this is the first continental analysis to quantify age78 based inequities in NCD management across all 54 African Union member states, the findings were informative to highlight UHC expansion has disproportionately benefited the working-age population, while the oldest-old face a widening risk gap in severe, untreated hypertension, particularly in Central and West Africa. The evidence collectively suggests that current Universal Health Coverage (UHC) frameworks in Africa are functionally age-stratified. The assumption that expanding general access will automatically protect vulnerable geriatric populations is flawed. Without specific safeguards, health systems appear to ration care implicitly by age. However, current Universal Health Coverage (UHC) frameworks often prioritize the economic core of the population, potentially creating a "Survival Penalty," a systemic withdrawal of care intensity as patients age beyond the workforce. Further the report on Tunisia as highlighted in the supplemental analyses as an outlier that maintains near-parity in diabetes treatment coverage across older age bands suggesting that system design and sustained primary care contact can mitigate age-related disparities. What would be best is to point out how other countries can learn from Tunisia and what health policy makers have to do further to enable UHC in its true sense to address the age related inequities in health care access. Reviewer #3: Thank you for the opportunity to review this manuscript. The study addresses a highly relevant and timely topic in global public health, examining age-related inequities in the management of hypertension and diabetes across African health systems. The continental scope, use of harmonised large-scale data, and clear policy relevance represent important strengths. Overall, the manuscript is well written, analytically sound, and conceptually innovative, and it has strong potential to contribute meaningfully to the literature. The comments below are intended to support further refinement of the manuscript and to help ensure alignment between interpretation, methodology, and journal expectations. Major comments 1. Framing and interpretation Given the ecological nature of the analysis and reliance on aggregated modelled data, some sections of the manuscript would benefit from slightly more cautious wording. In a few instances, the language may be interpreted as implying causal mechanisms or intentional system-level decision-making. I encourage the authors to consider reframing such statements using a more observational tone, ensuring that interpretations remain closely aligned with the study design. It would also be useful to include a brief statement acknowledging the ecological scope of the analysis and its interpretative boundaries. 2. Abstract and Results The abstract is clear and informative. Minor adjustments emphasizing quantitative findings and reducing conceptual terminology may further enhance clarity. Similarly, in the Results section, maintaining a descriptive approach and reserving interpretation primarily for the Discussion would improve structural consistency. 3. Methods clarity The methodological approach is appropriate and generally well described. However, the manuscript would benefit from additional clarification regarding: • the development and interpretation of newly introduced indicators; • statistical handling of modelled estimates and associated uncertainty; • justification for statistical approaches applied to aggregated data. If feasible, including a brief statement on robustness or sensitivity considerations would strengthen methodological transparency. 4. Discussion and Conclusion The Discussion is thoughtful and well contextualized within the existing literature. Minor restructuring to clearly separate principal findings, comparison with prior work, and limitations may improve readability. In addition, slightly moderating causal or normative language would help maintain scientific neutrality. The conclusion effectively summarizes the implications of the study; however, a more neutral closing tone focused on implications and future research directions may better align with journal style. 5. Presentation and references Figures and tables are informative and support the narrative well. Some minor stylistic adjustments toward a more neutral journal presentation (e.g., descriptive titles and consistent formatting) could improve presentation. Additionally, increasing reliance on peer-reviewed references where possible may further strengthen the manuscript. Overall recommendation This is a strong and important manuscript addressing a relevant global health issue. The suggested revisions are primarily related to clarification, tone, and presentation rather than major analytical concerns. I believe the manuscript will be substantially strengthened once these refinements are addressed. Reviewer #4: Title : The survival penalty: age-based inequities in hypertension and diabetes managementin African health systems (1990–2022) – a secondary quantitative analysis Version : 05 Mars 2026 Reviewer : Paulin Nkolamoyo Musungula Reviewer's report : This manuscript addresses a highly relevant issue in global health: age-related inequalities in the management of hypertension and diabetes within African health systems over an extended period (1990–2022). The choice of a secondary quantitative analysis spanning more than three decades represents a significant strength, as it enables the examination of structural trends and situates the question of inequities within a robust temporal perspective. The study has substantial scientific and programmatic potential, particularly in informing health equity policies and guiding the adaptation of health systems to ongoing demographic and epidemiological transitions. Overall, this is a timely and relevant study that could make an important contribution to the debate on intergenerational equity in health in Africa. However, several sections require clarification, and the manuscript could be improved as follows : Abstract The abstract is clear and relevant. However, terms such as “survival penalty,” “diagnostic paradox,” “care cliff,” “active exclusion,” and “therapeutic inertia” imply causal mechanisms. Given that the analysis is based on aggregated and modeled data, it would be preferable to present these concepts as descriptive or hypothetical interpretations, ensuring alignment between the conclusions and the nature of the data. Introduction 1. Lines 103–105: You present the concept of a “Survival Penalty” as a hypothesis, which is entirely legitimate and conceptually interesting. However, the wording “a systemic withdrawal of care intensity as patients age beyond the workforce” is relatively assertive and may give the impression that a structural mechanism has already been established. I would suggest clarifying more explicitly the exploratory nature of this proposition and adopting slightly more conditional language (for example, referring to a “possible association between advancing age and a reduction in the intensity of care”). Such a reformulation would preserve the conceptual strength of your hypothesis while avoiding any impression of a premature conclusion. Methods 1. Lines 141–145: You define the “Oldest-Old” group differently depending on the disease (75–79 years for hypertension and ≥85 years for diabetes). This complicates comparability between the analyses. It would be helpful to justify this difference or, if possible, harmonize the thresholds to strengthen consistency. 2. Lines 146–147: You use the term “Health System Ageism,” which implies systemic discrimination. Given that your data are aggregated and modeled, it would be more cautious to adopt more descriptive language, such as “age-related disparities in care,” to more accurately reflect what is actually measured. 3. Lines 148–157: You introduce the “Geriatric Drop-off Score” and the concept of “Therapeutic Inertia.” These indicators are interesting, but their limitations should be specified, including: the influence of selective mortality, disease prevalence, the limitations of modeled data, and the fact that therapeutic inertia traditionally implies clinician behavior, which is not directly measured here. 4. Lines 164–173: You use paired t-tests with N = 54 countries and a threshold of p < 0.05. It would be useful to clarify the assumptions of normality and independence and to discuss the issue of multiple comparisons. In addition, sex stratification is repeated in two places and could be consolidated for greater clarity. 5. Lines 161–162 and 169–170: You refer to the “Male Malus” and “Female Decline” hypotheses. These concepts are exploratory and somewhat normative. Their exploratory nature should be explicitly stated to avoid any causal interpretation. Results 1. Lines 185–191: You describe the “diagnostic paradox” for hypertension. It should be recalled that this term describes an observed phenomenon and does not imply causality. 2. Lines 193–198: The “care cliff” for diabetes shows a decline in coverage after age 70. It would be useful to remind readers that these observations are based on aggregated and modeled data and therefore do not allow inference about intentional actions by health systems. 3. Lines 200–206: The analysis of “untreated Stage 2 hypertension” and the concept of a “severity trap” are relevant, but it should be clarified that therapeutic inertia is inferred from the data and does not directly measure clinical practice. 4. Lines 222–231: The regional differences (“Exclusion vs. Neglect”) are interesting but should include a nuance regarding the variability in data quality and health system capacity across regions. 5. Lines 251–253: You highlight Tunisia as an example of “positive deviance.” It would be helpful to clarify that this is a descriptive observation and that structural or policy causes cannot be directly inferred. 6. Lines 256–263: The analysis of temporal trends (risk gap) is relevant, but it should be recalled that these measures are based on aggregated and modeled data. 7. Lines 270–288: The sex-specific analyses and the distinction between “therapeutic inertia” and “clinical hesitancy” are useful, but it should be emphasized that these categories are indirectly estimated and do not directly measure individual clinical behavior. Discussion The discussion is generally strong and relevant. However, terms such as “survival penalty,” “diagnostic paradox,” and “care cliff” should be used in a descriptive and hypothetical manner in order to avoid any causal or intentional interpretation of health system behavior, given the aggregated and modeled nature of the data used. Strengths and Limitations Although this study uses the largest harmonized dataset on NCD care in Africa, several limitations should also be acknowledged. The data are aggregated and modeled, derived from heterogeneous sources of varying quality, without individual cohort follow-up, and may be affected by selective mortality. The absence of individual clinical data prevents adjustment for comorbidities, frailty, or treatment adherence, and the inference of therapeutic inertia relies on observed gaps rather than directly measured behaviors. The use of different age thresholds for hypertension and diabetes limits comparability, and socioeconomic factors are not controlled for. Finally, the observed phenomena such as the “care cliff” or the “diagnostic paradox” should remain descriptive and hypothetical rather than being interpreted causally. Conclusion Lines 372–382: The terms “structural survival penalty” and “withdrawal of effective care” suggest intention or causality that has not been demonstrated. It would be preferable to reformulate them in a more descriptive and hypothetical manner, for example by referring to a “possible reduction in the intensity of care among the oldest age groups.” Reviewer #5: Review Comments to the Authors The manuscript presents an original study looking at age-based differences in non-communicable disease (NCD) care across Africa. This is an important topic, and the study provides useful information that could help guide policy and improve care for older adults. With chronic conditions like diabetes, hypertension, and heart disease becoming more common in aging populations, understanding where care gaps exist is very valuable. Significance The topic is timely and important. The findings help us understand where health systems may not be serving older adults well. This could support programs and policies aimed at making care more fair and accessible, especially in rural areas or underserved communities. Literature Context The authors cite important studies, but some points could be better supported by linking to more research. For example, when discussing how older adults may be excluded from care or guidelines, citing studies on geriatric care or health inequities would help. Comparing the results with data from other countries or regions could also make the findings easier to interpret. Methods The study design is generally appropriate, but more detail would make it clearer. For example, it would help to explain how participants were recruited, what the inclusion or exclusion criteria were, and if there were any changes to the original plan. Adding the full protocol or data collection tools as supplemental material would increase transparency. Also, it would be good to explain how countries with missing data were handled, even if the NCD-RisC imputation did this automatically. Data Availability Summary statistics are given, which is good, but the full or de-identified datasets should be shared according to PLOS rules. If there are reasons why the data can’t be shared, those should be clearly stated. Sharing the data makes it easier for other researchers to verify or build on the work. Results and Conclusions Most conclusions match the data. However, because this is an observational study, the authors should be careful about making causal claims. For example, instead of saying “older adults get worse care because of systemic neglect,” it would be better to say “older adults were less likely to receive recommended care, which may reflect systemic barriers.” This keeps the conclusions accurate without over-interpreting the findings. Reproducibility The methods are mostly clear, but adding more details about the tools used, how data collectors were trained, and how missing data were handled would help others repeat the study. This makes the research more reliable and useful for future studies. Ethics and Compliance Ethics approval and consent are mentioned, which is good and shows that the study follows standard research practices. Writing and Organization The manuscript is readable and well-organized. Some small improvements could make it even better, like simplifying long sentences, using consistent terms throughout, and adding more details in figure and table captions so the results are easy to understand. Reviewer #6: The topic is highly relevant for global health systems research, particularly given rapid demographic aging and increasing NCD burden in low- and middle-income countries. The use of large harmonized datasets covering multiple decades is a major strength. The paper is conceptually interesting and potentially impactful. However, this paper needs substantial methodological and conceptual refinements. I would like to have a clear understanding of the rationale for choosing the 50–54 age group as a reference rather than the full adult population. It would be helpful to have some clarity on the rationale for the difference between hypertensive and diabetic patients under the “Oldest-Old” category. The difference in age groups between HTN and DM reduces the comparability. Was the data weighted before being used for analysis? Providing a clear conceptual framework on how these indicators map onto health system behavior may be helpful for readers. It could be helpful for the reader if some of the interesting concepts, such as "survival penalty," “active exclusion,” and “therapeutic inertia,” are sufficiently grounded in existing literature or in a validated matrix. Given the structure of the data set (number of countries, years, age group, etc.), having a multilevel regression analysis would provide more robust inference. I think the author needs to be more cautious in case of framing the age-related disparities as direct evidence of ‘health system ageism.’ Is data on health financing, service availability, comorbidities, etc., available in this dataset? A conclusion regarding therapeutic inertia may sound overstated without including those variables. Providing the confidence intervals/statistical comparisons for comparisons would make it more robust. The discussion section is quite compelling in interpreting the age-related disparities in NCD care. However, I think there is still scope for explicit articulation of the link between the findings of this manuscript and the broader concept of systems responsiveness. There are lots of strengths of this study, like a large data set, a longitudinal perspective, and a focus on aging and NCDs. Clarifications on methodological aspects and conceptual refinement are necessary for the robustness of the study. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public. For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Abimbola Adegoke Reviewer #2: Yes: Dr. Somasundari Gopalakrishnan Reviewer #3: Yes: ALESSANDRA COELHO VIVEKANANDA MEIRELES Reviewer #4: No Reviewer #5: Yes: Neema W. Machumu Reviewer #6: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure Resubmissions: While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix. After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript. 31 Mar 2026 Submitted filename: Response to Reviewers PLOS - R1.docx 16 Jun 2026 PGPH-D-26-00316R1 The survival penalty: age-based inequities in hypertension and diabetes management in African health systems (1990–2022) – a secondary quantitative analysis. PLOS Global Public Health Dear Dr. Basil, Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 16 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Priyanka Roy, MD, MPH, PhD Academic Editor PLOS Global Public Health Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments (if provided): Minor changes Reviewer's report: The authors have overall responded in a thorough and satisfactory manner to all methodological comments. Without questioning the overall quality of the work, I remain nevertheless concerned about several points related to interpretation and wording, which would benefit from adjustment in order to ensure strict alignment between the data and the conclusions. 1. The following formulation remains problematic: “which likely leads to an underestimation of the true survival penalty (Line 370)”. It implicitly assumes the existence of a mechanism (“survival penalty”) that is not demonstrated by the study. A more neutral formulation would be preferable, for example: “may underestimate age-related differences in hypertension indicators”, in order to remain strictly descriptive and consistent with an ecological study design. 2. The manuscript does not explicitly discuss survivorship bias (healthy survivor effect), which is nevertheless essential for the interpretation of older age groups (75–79 years and ≥85 years). An appropriate correction would be to add an explicit limitation such as: “observed age gradients may partly reflect survivorship bias, as older age groups represent a selected subset of healthier survivors”. 3. Several statements remain overly interpretative, in particular: “implicit rationing (Line 381)”, “systems functioning in ways that are implicitly age-stratified (Line 392)”, and “care intensity does not consistently correlate with clinical need (Line 394)”. These formulations imply unmeasured mechanisms. A more rigorous version would be to rephrase in terms of descriptive associations, for example: “observed age-related differences in care cascade indicators suggest heterogeneity across age groups, without allowing inference on underlying mechanisms or on the appropriateness of care intensity”. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #4: (No Response) Reviewer #7: All comments have been addressed ********** 2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented. Reviewer #4: Yes Reviewer #7: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #4: Yes Reviewer #7: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #4: Yes Reviewer #7: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #4: Yes Reviewer #7: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #4: Title : The survival penalty : age-based inequities in hypertension and diabetes managementin African health systems (1990–2022) – a secondary quantitative analysis Version : 22 May 2026 Reviewer : Paulin Nkolamoyo Musungula Reviewer's report : The authors have overall responded in a thorough and satisfactory manner to all methodological comments. Without questioning the overall quality of the work, I remain nevertheless concerned about several points related to interpretation and wording, which would benefit from adjustment in order to ensure strict alignment between the data and the conclusions. 1. The following formulation remains problematic: “which likely leads to an underestimation of the true survival penalty (Line 370)”. It implicitly assumes the existence of a mechanism (“survival penalty”) that is not demonstrated by the study. A more neutral formulation would be preferable, for example: “may underestimate age-related differences in hypertension indicators”, in order to remain strictly descriptive and consistent with an ecological study design. 2. The manuscript does not explicitly discuss survivorship bias (healthy survivor effect), which is nevertheless essential for the interpretation of older age groups (75–79 years and ≥85 years). An appropriate correction would be to add an explicit limitation such as: “observed age gradients may partly reflect survivorship bias, as older age groups represent a selected subset of healthier survivors”. 3. Several statements remain overly interpretative, in particular: “implicit rationing (Line 381)”, “systems functioning in ways that are implicitly age-stratified (Line 392)”, and “care intensity does not consistently correlate with clinical need (Line 394)”. These formulations imply unmeasured mechanisms. A more rigorous version would be to rephrase in terms of descriptive associations, for example: “observed age-related differences in care cascade indicators suggest heterogeneity across age groups, without allowing inference on underlying mechanisms or on the appropriateness of care intensity”. Reviewer #7: The authors have addressed all previous reviewers' comments adequately. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public. For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #4: No Reviewer #7: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure Resubmissions: While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix. After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript. 19 Jun 2026 Submitted filename: Response to Reviewers PLOS - R2.docx 30 Jun 2026 The survival penalty: age-based inequities in hypertension and diabetes management in African health systems (1990–2022) – a secondary quantitative analysis. PGPH-D-26-00316R2 Dear Dr Basil, We are pleased to inform you that your manuscript 'The survival penalty: age-based inequities in hypertension and diabetes management in African health systems (1990–2022) – a secondary quantitative analysis.' has been provisionally accepted for publication in PLOS Global Public Health. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health. Best regards, Priyanka Roy, MD, MPH, PhD Academic Editor PLOS Global Public Health *********************************************************** Reviewer Comments (if any, and for reference):